FMP
Pacific Biosciences of California, Inc.
PACB
NASDAQ
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
1.36 USD
-0.02 (-1.47%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
39.22M
39.97M
36.01M
38.81M
29.17M
29.96M
30.07M
34.38M
10.06M
10M
5.94M
4.43M
132.72M
69.26M
68.3M
85.86M
27.47M
25.52M
38.48M
43.45M
41.64M
43.75M
45.88M
42.41M
0
0
0
0
0
0
0
0
63.61M
0
67.35M
6.76M
-122.66M
-59.26M
-145.77M
-81.43M
125.35M
-1.47M
-27.55M
3.18M
2.69M
-60.73M
-173.32M
-78.18M
316k
0
0
11.97M
2.37M
-60.73M
-173.32M
-78.18M
0.01
-0.22
-0.64
-0.29
0.01
-0.22
-0.64
-0.29
283M
272.92M
272.38M
269.58M
306.89M
272.92M
272.38M
269.58M
-122.66M
-41.09M
-155.49M
-62.59M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-2.15B
-2.09B
-1.92B
-1.84B
2.37M
-60.73M
-173.32M
-78.18M
0
0
0
0
0
0
0
0
0
-2.15B
-2.09B
-1.92B
2.15B
-60.73M
-173.32M
-78.18M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
46.6M
49.3M
57.3M
67.96M
10.95M
16.1M
14.29M
12.01M
-1.62M
787k
-1.48M
-3.88M
37.26M
32.41M
44.49M
59.83M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-55.1M
0
-93.2M
0
369.06M
369.06M
462.26M
462.26M
313.96M
369.06M
369.06M
462.26M
All figures are in USD.